Systemic immunosuppressive treatment

**Background:** Dupilumab is the first biologic registered for the treatment of moderate-to-severe atopic dermatitis (AD) and efficacy was shown in phase III clinical trials (primary outcome at week 16 was reached in 38% of patients). Currently, …